GlassScriptPhysician profile
Jodi Dome Linger
NPI 1376750604
$1,100.12
in general payments reported to CMS, 2019-2025
15 companies · $61.32 in 2025
The $61.32 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $189 · 2021: $54.67 · 2022: $16.60 · 2023: $243 · 2024: $186 · 2025: $61.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Education: $38.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.20 |
| Education | $38.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $292.93 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $190.46 | 2019-2024 | Auryxia |
| Amgen INC. | $139.11 | 2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $83.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $75.75 | 2019-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $63.88 | 2019-2020 | |
| Vifor Pharma, INC. | $51.98 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $45.27 | 2019-2020 | |
| Ardelyx, INC. | $43.33 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $30.95 | 2023 | |
| Travere Therapeutics, INC. | $24.49 | 2023-2024 | |
| Nxstage Medical, INC. | $17.99 | 2025 | Pureflow Sl, Nxstage System One |
| Pharmacyclics LLC, An Abbvie Company | $14.20 | 2023 | Imbruvica |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Genzyme Corporation | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Linger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.